Like all drug companies--especially the industry giants--Pfizer needs a productive research and development program to drive growth. The company is confident its recent moves will go a long way toward achieving that goal. STAT News reported last week that Albert Bourla, who took over as CEO in January, told analysts on a conference call that Pfizer will be a very different company, one that is even better equipped to fulfill its purpose of bringing to market "breakthroughs that change patients' lives."